Cargando…
Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection
The emergence of the SARS-CoV-2 variants of concern has greatly influenced the immune correlates of protection, and there are little data about the antibody threshold concentrations to protect against infection with SARS-CoV-2 Omicron BA.1 or BA.2. We analyzed the antibody responses of 259 vaccinate...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506424/ https://www.ncbi.nlm.nih.gov/pubmed/36146626 http://dx.doi.org/10.3390/vaccines10091548 |
_version_ | 1784796719473491968 |
---|---|
author | Dimeglio, Chloé Migueres, Marion Bouzid, Naémie Chapuy-Regaud, Sabine Gernigon, Caroline Da-Silva, Isabelle Porcheron, Marion Martin-Blondel, Guillaume Herin, Fabrice Izopet, Jacques |
author_facet | Dimeglio, Chloé Migueres, Marion Bouzid, Naémie Chapuy-Regaud, Sabine Gernigon, Caroline Da-Silva, Isabelle Porcheron, Marion Martin-Blondel, Guillaume Herin, Fabrice Izopet, Jacques |
author_sort | Dimeglio, Chloé |
collection | PubMed |
description | The emergence of the SARS-CoV-2 variants of concern has greatly influenced the immune correlates of protection, and there are little data about the antibody threshold concentrations to protect against infection with SARS-CoV-2 Omicron BA.1 or BA.2. We analyzed the antibody responses of 259 vaccinated healthcare workers, some of whom had been previously infected by SARS-CoV-2. The median follow-up was 179 days (IQR: 171–182) after blood collection. We detected 88 SARS-CoV-2 Omicron infections during the follow-up period, 55 (62.5%) with SARS-CoV-2 BA.1, and 33 (37.5%) with SARS-CoV-2 BA.2. A neutralizing antibody titer below 8 provided no protection against a BA.1 infection, a titer of 16 or 32 gave 73.2% protection, and a titer of 64 or 128 provided 78.4% protection. Conversely, the BA.2 infection rate did not vary as a function of anti-BA.2 neutralizing antibody titers. Binding antibody concentrations below 6000 BAU/mL provided no protection against Omicron BA.1 infection, 6000–20,000 BAU/mL provided 55.6% protection, and 20,000 or more provided 87.7% protection. There was no difference in BA.2 infection depending on the binding antibody concentration. Further studies are needed to investigate the relationship between antibody concentrations and infection with the Omicron BA.4/5 variants that are becoming predominant worldwide. |
format | Online Article Text |
id | pubmed-9506424 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95064242022-09-24 Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection Dimeglio, Chloé Migueres, Marion Bouzid, Naémie Chapuy-Regaud, Sabine Gernigon, Caroline Da-Silva, Isabelle Porcheron, Marion Martin-Blondel, Guillaume Herin, Fabrice Izopet, Jacques Vaccines (Basel) Article The emergence of the SARS-CoV-2 variants of concern has greatly influenced the immune correlates of protection, and there are little data about the antibody threshold concentrations to protect against infection with SARS-CoV-2 Omicron BA.1 or BA.2. We analyzed the antibody responses of 259 vaccinated healthcare workers, some of whom had been previously infected by SARS-CoV-2. The median follow-up was 179 days (IQR: 171–182) after blood collection. We detected 88 SARS-CoV-2 Omicron infections during the follow-up period, 55 (62.5%) with SARS-CoV-2 BA.1, and 33 (37.5%) with SARS-CoV-2 BA.2. A neutralizing antibody titer below 8 provided no protection against a BA.1 infection, a titer of 16 or 32 gave 73.2% protection, and a titer of 64 or 128 provided 78.4% protection. Conversely, the BA.2 infection rate did not vary as a function of anti-BA.2 neutralizing antibody titers. Binding antibody concentrations below 6000 BAU/mL provided no protection against Omicron BA.1 infection, 6000–20,000 BAU/mL provided 55.6% protection, and 20,000 or more provided 87.7% protection. There was no difference in BA.2 infection depending on the binding antibody concentration. Further studies are needed to investigate the relationship between antibody concentrations and infection with the Omicron BA.4/5 variants that are becoming predominant worldwide. MDPI 2022-09-17 /pmc/articles/PMC9506424/ /pubmed/36146626 http://dx.doi.org/10.3390/vaccines10091548 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Dimeglio, Chloé Migueres, Marion Bouzid, Naémie Chapuy-Regaud, Sabine Gernigon, Caroline Da-Silva, Isabelle Porcheron, Marion Martin-Blondel, Guillaume Herin, Fabrice Izopet, Jacques Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection |
title | Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection |
title_full | Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection |
title_fullStr | Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection |
title_full_unstemmed | Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection |
title_short | Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection |
title_sort | antibody titers and protection against omicron (ba.1 and ba.2) sars-cov-2 infection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506424/ https://www.ncbi.nlm.nih.gov/pubmed/36146626 http://dx.doi.org/10.3390/vaccines10091548 |
work_keys_str_mv | AT dimegliochloe antibodytitersandprotectionagainstomicronba1andba2sarscov2infection AT migueresmarion antibodytitersandprotectionagainstomicronba1andba2sarscov2infection AT bouzidnaemie antibodytitersandprotectionagainstomicronba1andba2sarscov2infection AT chapuyregaudsabine antibodytitersandprotectionagainstomicronba1andba2sarscov2infection AT gernigoncaroline antibodytitersandprotectionagainstomicronba1andba2sarscov2infection AT dasilvaisabelle antibodytitersandprotectionagainstomicronba1andba2sarscov2infection AT porcheronmarion antibodytitersandprotectionagainstomicronba1andba2sarscov2infection AT martinblondelguillaume antibodytitersandprotectionagainstomicronba1andba2sarscov2infection AT herinfabrice antibodytitersandprotectionagainstomicronba1andba2sarscov2infection AT izopetjacques antibodytitersandprotectionagainstomicronba1andba2sarscov2infection |